1. Home
  2. BANL vs ACXP Comparison

BANL vs ACXP Comparison

Compare BANL & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BANL

CBL International Limited

N/A

Current Price

$3.07

Market Cap

6.1M

Sector

Energy

ML Signal

N/A

Logo Acurx Pharmaceuticals Inc.

ACXP

Acurx Pharmaceuticals Inc.

N/A

Current Price

$0.96

Market Cap

5.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BANL
ACXP
Founded
2015
2017
Country
Malaysia
United States
Employees
N/A
N/A
Industry
Oil Refining/Marketing
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.1M
5.8M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
BANL
ACXP
Price
$3.07
$0.96
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $17.00
AVG Volume (30 Days)
15.5K
★ 86.5K
Earning Date
08-18-2026
11-12-2026
Dividend Yield
★ 3.42%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.27
$0.95
52 Week High
$16.40
$7.54

Technical Indicators

Market Signals
Indicator
BANL
ACXP
Relative Strength Index (RSI) 40.76 32.44
Support Level $2.77 $0.95
Resistance Level $5.18 $1.77
Average True Range (ATR) 0.35 0.07
MACD 0.08 0.00
Stochastic Oscillator 11.59 12.81

Price Performance

Historical Comparison
BANL
ACXP

About BANL CBL International Limited

CBL International Ltd is a marine fuel logistics company that provides a one-stop solution for vessel refueling. In the bunkering industry, it is referred to as a bunkering facilitator. It facilitates vessel refueling between ship operators and local physical distributors/traders by purchasing marine fuel, including fossil fuel and alternative fuel, from its suppliers and arranging for the suppliers to deliver the fuel to the customers. The company's customer base comprises container liners, bulk carriers, and tankers. Geographically, the company generates a majority of its revenue from China, followed by Hong Kong, Malaysia, Singapore, South Korea, and other regions.

About ACXP Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.

Share on Social Networks: